Clinical Trial Update: Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing neoadjuvant chemotherapy plus a bispecific antibody versus a monoclonal antibody in locally advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING